Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

Over the past three decades, there has been a startling increase in the prevalence of obesity across the U.S., at least ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

People living with HIV may also have to manage other health conditions like cardiovascular disease, type 2 diabetes, ...

"We have seen an alarming rise in diabetes over the past three decades, which reflects the increase in obesity, compounded by the impacts of the marketing of unhealthy food, a lack of physical ...

The study predicts devastating trends at the population level.

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Foundation is pleased to announce the 2024?2025 recipients of the Incentive Grants for Practitioner Innovation in Pharmaceutical Care and the Practice Advancement Grants. A total of 53 pharmacists ...